Phase II study of doxifluridine in advanced colorectal adenocarcinoma
| Autor: | Eduard E. Holdener, Pierre Alberto, Victor Hofmann, P. Siegenthaler, Reto Abele, Susanna Kaplan, Ryssel Hj, Diethelm Hartmann, Franco Cavalli |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Chemical Phenomena Vomiting Colorectal cancer Nausea medicine.medical_treatment Phases of clinical research Rectum Antineoplastic Agents Adenocarcinoma Gastroenterology Rectosigmoid Adenocarcinoma Internal medicine medicine Humans Aged Chemotherapy Rectal Neoplasms business.industry Cancer Heart Leukopenia Middle Aged medicine.disease Thrombocytopenia Chemistry medicine.anatomical_structure Oncology Colonic Neoplasms Drug Evaluation Female Drug Eruptions medicine.symptom Floxuridine business |
| Zdroj: | Journal of Clinical Oncology. 1:750-754 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Doxifluridine, a new fluoropyrimidine derivative, was tested in a cooperative phase II trial by the Swiss Group for Clinical Cancer Research in advanced measurable colorectal cancer. The drug was given in a five consecutive day schedule by a bolus intravenous injection at a dose of 4 g/m2 per day and repeated every three to four weeks. Of 42 eligible patients, 40 had no previous chemotherapy. Response was defined in 27 patients having received two or more courses of doxifluridine. Seven responses (26%) were observed. Responses were seen only in sigmoid and rectum primary tumors. Toxicity consisted mainly of leukopenia (53% of the evaluable patients), nausea and vomiting (38%). Other toxicities such as dermatitis, myocardial injury, and hair loss were also observed. Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|